Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive Stage Small Cell Lung Cancer

Trial Profile

Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive Stage Small Cell Lung Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Trilaciclib (Primary) ; Atezolizumab; Carboplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors G1 Therapeutics
  • Most Recent Events

    • 05 Mar 2018 According to a G1 Therapeutics media release, the company plans to share data from this trial with U.S. and European regulatory authorities and also plans to present the results at a medical meeting later in 2018.
    • 05 Mar 2018 Top-line results presented in a G1 Therapeutics media release.
    • 21 Feb 2018 According to a G1 Therapeutics media release, the company anticipates announcement of topline data from this trial in March 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top